[{"id":"3ec131cc-474f-4650-87ca-8c361b078d2c","acronym":"HD-CAR-1","url":"https://clinicaltrials.gov/study/NCT03676504","created_at":"2021-03-26T10:04:03.773Z","updated_at":"2024-07-02T16:35:46.195Z","phase":"Phase 1/2","brief_title":"Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR","source_id_and_acronym":"NCT03676504 - HD-CAR-1","lead_sponsor":"University Hospital Heidelberg","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HD-CAR-1"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/07/2018","start_date":" 09/07/2018","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-06-08"}]